



Ref: OPL/Share/2018/13
January 28, 2018

Managing Director
Dhaka Stock Exchange Ltd
9/F Motijheel C/A
Dhaka-1000.

Subject : Price Sensitive Information.

Dear Sir,

As per rule no. 33 of the DSE Listing Regulations, 2015, the Board of Directors of Orion Pharma Limited has adopted its **un-audited Half-Yearly financial statements** in its Board Meeting held on January 28, 2018 at 4:30 pm in the registered office at Orion House, 153-154, Tejgaon I/A, Dhaka-1208. The following decisions were taken in the meeting :

	December 31, 2017	December 31, 2016
Consolidated Earnings Per Share (EPS)- Q2	: BDT. 2.07	BDT. 2.46
Consolidated NAV per Share - Q2 (Including Revaluation Surplus)	: BDT. 71.46	BDT. 70.72
Consolidated NAV per Share - Q2 (Excluding Revaluation Surplus)	: BDT. 63.06	BDT. 62.17
Consolidated Net Operating Cash Flow Per Share (NOCFPS) - Q2	: BDT. 4.81	BDT. 3.22

Please acknowledge the receipt.

Thanking you,

Sincerely yours'

Md. Ferdous Jaman
Company Secretary